This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
ICON (ICLR) Up 7.6% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
ICON (ICLR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Pediatrix Medical Group, Inc. (MD) Up 11% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Pediatrix Medical Group, Inc. (MD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Pediatrix's (MD) Q4 Earnings Miss Due to Soft Patient Volumes
by Zacks Equity Research
Pediatrix's (MD) Q4 results were hit by an increase in overall cost level resulting from higher same-unit clinical compensation costs. Yet, an impressive 2024 adjusted EBITDA guidance is likely to provide relief to investors.
Pediatrix Medical Group (MD) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
Although the revenue and EPS for Pediatrix Medical Group (MD) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Will High Expenses Ail Pediatrix Medical's (MD) Q4 Earnings?
by Zacks Equity Research
Pediatrix Medical's (MD) Q4 results are likely to be hurt by an increase in practice salaries and benefits expense as well as softer patient volumes, partly offset by same-unit pricing growth.
Pediatrix (MD) Q3 Earnings Miss on High Costs, Shares Down 12%
by Zacks Equity Research
Pediatrix's (MD) third-quarter results suffer from the decline in same-unit revenues attributable to patient volume. Management currently expects 2023 adjusted EBITDA to be within $200-$210 million.
Pediatrix Medical Group (MD) Lags Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Pediatrix Medical Group (MD) delivered earnings and revenue surprises of -25.58% and 0.43%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Establishment Labs Holdings Inc. (ESTA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Establishment Labs Holdings Inc. (ESTA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Revvity (RVTY) Misses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Revvity (RVTY) delivered earnings and revenue surprises of -0.84% and 3.10%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Pediatrix Medical Group (MD) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Pediatrix Medical Group (MD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MD or DOCS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
MD vs. DOCS: Which Stock Is the Better Value Option?
Why Investors Are Retaining Pediatrix Medical (MD) Stock Now
by Zacks Equity Research
Pediatrix Medical's (MD) rising net patient service revenues will likely benefit its top line.
Pediatrix Medical Group (MD) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
The headline numbers for Pediatrix Medical Group (MD) give insight into how the company performed in the quarter ended June 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Pediatrix (MD) Q2 Earnings Meet Estimates, Revenues Up Y/Y
by Zacks Equity Research
Pediatrix (MD) reiterates adjusted EBITDA guidance in the range of $235-$245 million for 2023 compared with $241 million in 2022.
Pediatrix Medical Group (MD) Meets Q2 Earnings Estimates
by Zacks Equity Research
Pediatrix Medical Group (MD) delivered earnings and revenue surprises of 0% and 1.23%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
MD vs. PGNY: Which Stock Is the Better Value Option?
by Zacks Equity Research
MD vs. PGNY: Which Stock Is the Better Value Option?
Strength Seen in Surgery Partners (SGRY): Can Its 5.0% Jump Turn into More Strength?
by Zacks Equity Research
Surgery Partners (SGRY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Why Is Pediatrix Medical Group (MD) Down 4.9% Since Last Earnings Report?
by Zacks Equity Research
Pediatrix Medical Group (MD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Pediatrix (MD) Down 4.2% Despite Q1 Earnings & Revenue Beat
by Zacks Equity Research
Investors are likely concerned about Pediatrix's (MD) lower enrollment in commercial insurance programs, escalating practice salaries and benefits and net borrowings.
Pediatrix Medical Group (MD) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Pediatrix Medical Group (MD) delivered earnings and revenue surprises of 4.55% and 0.75%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Organon (OGN) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Organon (OGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Pediatrix Medical Group (MD) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Pediatrix Medical Group (MD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Pediatrix (MD) Q4 Earnings miss on High Operating Expenses
by Zacks Equity Research
Pediatrix (MD) anticipates 2023 adjusted EBITDA to be within $235-$245 million.
Pediatrix Medical Group (MD) Lags Q4 Earnings Estimates
by Zacks Equity Research
Pediatrix Medical Group (MD) delivered earnings and revenue surprises of -4.08% and 2.43%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Teladoc (TDOC) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Teladoc (TDOC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.